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Thyroid hormone plays a crucial role in the development and function of the nervous system. In order to bind to its nuclear
receptor and regulate gene transcription thyroxine needs to be activated in the brain. This activation occurs via conversion of
thyroxine to T3, which is catalyzed by the type 2 iodothyronine deiodinase (D2) in glial cells, in astrocytes, and tanycytes in
the mediobasal hypothalamus. We discuss how thyroid hormone aﬀects glial cell function followed by an overview on the ﬁne-
tuned regulation of T3 generation by D2 in diﬀerent glial subtypes. Recent evidence on the direct paracrine impact of glial D2
on neuronal gene expression underlines the importance of glial-neuronal interaction in thyroid hormone regulation as a major
regulatory pathway in the brain in health and disease.
1.Introduction
Thyroid hormone is a fundamental regulator of biological
processes, including cell proliferation, diﬀerentiation, and
metabolic balance [1]. Thyroid hormone plays a crucial role
in brain development, which is illustrated by the dramatic
neurologic impairment observed in untreated neonatal
hypothyroidism, a condition leading to cretinism [2–4]. The
adult brain is also sensitive to thyroid hormone in view of
mood disorders, depression, memory, cognitive and motoric
impairments frequently observed in hypothyroid patients
[5].
The major secretory product of the human thyroid gland
is thyroxine (T4), a prohormone that does not eﬃciently
bind thyroid hormone receptor (TR). T4 has to be converted
to 3,5,3-triiodothyronine (T3) in order to bind to TR
and initiate thyroid hormone-mediated changes in gene
expression proﬁles. Notably, a signiﬁcant amount of brain
T3 is derived from the local activation of prohormone T4
to T3 (80% in the cortex), suggesting that most T3 acting
in the brain is generated in situ from T4 deiodination
[6]. Plasma T3 was also shown to enter the brain [7],
and studies on the monocarboxylate transporter 8 (MCT8)
knock-out mice indicate that MCT8 plays an important role
in this process, but other transporters might also be involved
[8, 9]. However, only supraphysiological doses of T3 were
suﬃcient to suppress pro-TRH mRNA in the hypothalamic
paraventricular nucleus of hypothyroid rats [10] indicating
that T4 uptake into the brain is important for normal
function of T3-mediated processes in this tissue. Further
studies are required to better understand the transport of
diﬀerent thyroid hormone derivatives across the blood-brain
and CSF-brain barrier, the consequences of this mechanism,
and the factors aﬀecting this process (see also Section 3.3).
LocalT3generationinthebrainiscatalyzedbythetype2
deiodinase (D2), a tightly controlled selenoenzyme [11–14].
D2 is the only known protein capable of producing T3 in
the human brain [15]. Beyond D2-mediated T3 generation,
type3deiodinase (D3)isalsosimilarlyimportantforthyroid
hormone economy in the brain [16, 17]. D3 inactivates T3
and converts T4 to reverse-T3 that cannot bind to TR. Thus,
in contrast to D2, D3 catalyzes the inactivation pathway of
thyroid hormone metabolism.
D2 is expressed in glial cells, including astrocytes in
diﬀerent brain regions and tanycytes, the specialized glial
cells in the walls and ﬂoor of the third ventricle of the
mediobasal hypothalamus [18–20]. In contrast to the glial
D2, D3 expression in the brain is restricted to neurons [21].2 Journal of Thyroid Research
While historically glial elements of the brain were viewed
a sat y p eo fc o n n e c t i v et i s s u eo ft h eC N Sw i t h o u ta n yr e a l
function, this view was overturned by the abundant data
on the complex role of glial cells in brain metabolism [22].
According to this more recent hypothesis, glial D2 provides
T3 for neighboring neurons that express TR but lack T3
generating capacity [4, 19, 20, 23–25].
Thyroid hormone exerts its biological eﬀects predomi-
nantlyviabindingtoitsnuclearTR,butspeciﬁcnongenomic
eﬀects have also been suggested [26–29]. Two TR isoforms,
α and β, act as ligand-regulated transcription factor and
have a central role in transducing the hormonal signal into a
cellular response in the brain (reviewed in [30, 31]). Despite
accumulating evidence demonstrating that thyroid hormone
alters astrocytes function (see Section 2), the presence of TR
in astrocytes remains controversial.
The presence of TR in astrocytes has been suggested
by in vitro studies [32–34], but lower receptor concentra-
tions have been detected compared to oligodendrocytes or
neurons [34]. The presence of TR could also be detected
in puriﬁed glial nuclei from postnatal rat brain [35]. In
contrast, in vivo data suggested that thyroid hormone would
mediate astrocyte function indirectly, based on the lack of
immunoﬂuorescence staining of TR receptor isoforms α1,
β1, and β2 in GFAP positive astrocytes of the adult rat brain
[36]. Interestingly the same group used immunoﬂuorescent
to locate TR in cultured astrocytes [37], in line with other
in vitro data. Astrocytes from distinct developing brain
regions are diﬀerently responsive to thyroid hormone, with
the highest sensitivity in the hemispheres [38]. Thyroid
hormonehasbeenshowntobeessentialformaturationofrat
cerebellar astrocytes [39], and TRα1 knock-out mice display
astrocyte maturation defects suggesting the role of this TR
isoform to mediate a direct eﬀect of thyroid hormone action
in astrocytes [40]. Presently, most studies agree with the
presenceofTRα1isoforminastrocytes;discrepanciesremain
in the case of TRβ receptor subtypes. Expression of diﬀerent
TR isoforms has been reported in human astrocytomas
[41]. Thyroid hormone action occurs within limited time
windows, a spatially and timely controlled phenomenon.
Cultured cells and most astrocytomas are devoid of the
same control conditions, which normally act on cells in
the brain, and this could be a background of the diﬀerent
experimental results obtained between in vitro and in vivo
data. In addition, cultured astrocytes are most likely reactive
astrocytes, and the heterogeneity of the in vitro experimental
results regarding TR expression in these cells may reﬂect the
diﬀerent experimental conditions, such as the brain region
andtheageoftheanimalsusedforcultivationorthediﬀerent
culture conditions.
Active transport of thyroidhormone into brain cellsadds
tothecomplexityofthyroidhormoneeconomyinthecentral
nervous system [42, 43]. The MCT8 (SLC16A2) and organic
anion transporter 1C1 (OATP1C1) are the best studied
thyroid hormone transporters [44, 45]. MCT8 seems to be
the predominant neuronal T3 transporter, and its mutations
are associated with the Allan-Herndon-Dudley syndrome
characterized by congenital hypotonia that progresses to
spasticity with severe psychomotor delays [44, 46, 47].
OATP1C1 has high aﬃnity to T4 and is expressed in brain
endothelial cells and also in vascular end-feet of astrocytes
[48]. Interestingly, tanycytes seem to coexpress MCT8 and
OATP1C1 [48]. Other thyroid hormone transporters have
also been identiﬁed including MCT10, which seems to
transportT3moreeﬀectivelythanMCT8[49]andtheL-type
amino acid transporters (LATs) [50]. MCT10 expression was
demonstrated in microglia while LAT1 and LAT2 expression
was found both in astrocytes and neurons; LAT2 was also
present in microglia [51]. Studies on the MCT8 deﬁcient
mouse revealed that in the absence of functional MCT8,
alternative thyroid hormone transporters play an important
complementary role in neuronal T3 transport. In contrast,
the lack of alternative pathways, for example, LAT2 in devel-
oping human neurons, might be involved in the devastating
neurodevelopmental phenotype seen in MCT8-deﬁcient
patients with Allan-Herndon-Dudley syndrome [8, 52].
Studies on transgenic mice with targeted inactivation of
diﬀerent members of the deiodinase enzyme family, MCT8,
or their combined deletion provided important information
on the complex nature of functional interactions between
factors regulating thyroid hormone metabolism and trans-
port in the brain and other tissues [8, 9, 53–58]. Despite the
relatively mild brain phenotype of D2KO or MCT8KO mice,
their combined inactivation led to aggravated manifestation
of thyroid hormone deprivation and resulted in similar
eﬀects as observed in hypothyroidism [9, 59]. These data
conﬁrmed the crucial role of D2 in local T3 generation in
the brain and suggested that changes in D2 expression could
compensate for defects in MCT8 function in the rodent
brain.
Numerous aspects of deiodinase-mediated changes of
thyroid hormone metabolism have been carefully reviewed
and provide a comprehensive view on the molecular and
biochemical properties, structure, regulation, and biological
functions of these enzymes in the brain and diﬀerent tissues
[24,60–69].Inthepresentpaperwewillfocusontheroleand
regulation of thyroid hormone in neuroglia, representing
an exciting aspect of emerging signiﬁcance for thyroid
hormone economy. We provide a concise overview on the
most important eﬀects of thyroid hormone on glial cells,
followedbythediscussionofnoveldataonD2-mediatedglial
T3 generation and its role under speciﬁc physiological and
pathophysiological conditions.
2. Thyroid Hormone-Mediated Changes in
Neuroglial Cells
Brain development provides the best studied model of
thyroid hormone action in the brain. It has been known for
decades that hypothyroidism can result in numerous brain
defects, including decreased dendritic arborization of Purk-
inje cells, diminished axonal outgrow and myelinization,
and insuﬃcient cortical layer organization [70]. Although
thyroidhormonealsoimpactstheadultbrain,theunderlying
cellular and molecular events are less understood [71, 72].
Variousaspectsofthyroidhormone-mediatedbrainfunction
were extensively reviewed (see Section 1).Journal of Thyroid Research 3
Available data on thyroid-hormone-regulated gene net-
works are yet limited, but accumulating evidence indicates
that various sets of genes are regulated along this pathway.
In a recent study, thyroid hormone action on adult rat
striatumwasmonitoredusinggeneexpressionproﬁling[73].
The numerous up or down regulated sets of genes involved
various pathways aﬀecting for example, circadian regulation,
oxidative stress response, phenylethylamine degradation,
MAPK pathway, phosphate metabolism, signal transduction,
and cell structure. These ﬁndings revealed novel aspects
of brain related thyroid hormone action that need to be
studied in details. Numerous examples of thyroid hormone-
dependent gene expression in the brain are related to
neurons, which could be a result of direct neuronal eﬀect
or an indirect glia-mediated signal [74]. Neuroglial cells are
heavily involved in the regulation of neuronal metabolism
and activity, glucose supply, cerebral blood ﬂow, and neu-
rotransmitter levels in mature brain [22]. The detailed
description of mechanisms how glial cells are involved in
this process is an ongoing eﬀort and requires further studies.
We will brieﬂy summarize below how thyroid hormone
targets glial cells and mediates their function that has also
consequence on glia-mediated neuronal activities.
2.1. Diﬀerentiation, Maturation. Thyroid hormone aﬀects
the diﬀerentiation and maturation of diﬀerent glial sub-
types including astrocytes, oligodendrocytes, and microglia
[75–77]. Although many aspects of glial linages are yet
controversial, evidence has been obtained in vitro that
oligodendrocytes and astrocytes are derived from a common
precursor, the glial restricted precursor cells (GRP) [78].
GRPs are tripotential cells, owning the ability to divide into
myelinproducingoligodendrocyteortwotypesofastrocytes,
depending on the factors contained in growth medium.
In vitro studies demonstrated that mature oligodendrocytes
were developed from precursor cells in the presence of
thyroid hormone and platelet-derived growth factor (PDGF)
[79]. The concept that these two glial cell types originate
from a common lineage was also supported by ﬁndings
that show reciprocal changes in oligodendrocyte/astrocyte
cell density in the rat white matter upon changes in
serum T4 level [80]. Furthermore, the number of matured
oligodendrocytes and astrocytes was reduced in the brain
of hypothyroid animals within white matter tracts [81, 82].
Morphological diﬀerentiation of astrocytes from progenitors
to mature cells has been explained by thyroid hormone-
mediated actions aﬀecting cytoskeletal proteins (F-actin,
GFAP) [40, 83]. In hypothyroid neonatal rats, there was
reduced GFAP content in hippocampus and basal forebrain
[84]. In cell cultures, T3 upregulates GFAP production
and reorganizes GFAP ﬁlaments and transforms the ﬂat
polygonal astrocytes into process-bearing cells [85, 86].
Not only T3, but T3-mediated growth factor secretion can
enhance GFAP expression, thanks to several growth factor
binding domains in its promoter region [87, 88].
Microglial cell development is also aﬀected by thyroid
hormone. In the cortical forebrain of hypothyroid neonatal
rat there is diminished amount of cell bodies and less
abundant microglial process density. T3 favored survival of
microglias in vitro and have triggered their process extension
[77, 89].
The mechanisms by which thyroid hormone promotes
diﬀerentiation were not yet fully revealed, but there are
several candidates for this process, for example, cell-cycle
modulators like E2F-1, cyclin D1, and p27 [90]. E2F1 is
a key transcription factor, that controls G1 to S phase
transition and has an impact on cyclin D1 [91]. E2F-1 and
cyclin D1 expression is down regulated via TR-mediated
transcriptional repression [92, 93]. Another candidate of
this pathway, p27 cyclin-dependent kinase inhibitor was
upregulated in response to T3 [94, 95]. Decreased amount of
E2F-1 and cyclin D1 protein and increased levels of the p27
cell-cycle inhibitor may shift cell fate towards diﬀerentiation.
2.2. Myelination. Myelination represents the best character-
ized T3-dependent glial action in the brain [96–98]. Thy-
roid hormone regulates oligodendrocyte diﬀerentiation and
myelin production via TR-mediated transcriptional eﬀects
[34, 99]. Thyroid hormone depletion resulted in delayed
expression of oligodendrocyte-speciﬁc markers [100]a n d
decreased the number of oligodendrocyte cell bodies in the
main white matter tracts [81]. Hypothyroidism delayed the
expression of genes encoding structural proteins of myelin,
forexample,myelinbasicprotein(MBP),proteolipidprotein
(PLP), and myelin-associated glycoprotein (MAG) [101]a n d
resulted in reduced numbers of myelinated axons and lower
myelin content [102]. Sensitivity period of these genes for
thyroid hormone extends from the end of the ﬁrst postnatal
week up to the end of the ﬁrst month in rat [76, 103].
2.3. Extracellular Matrix Formation and Cytoskeleton Orga-
nization. Thyroid hormone action on astrocytes during
brain development is illustrated by enhanced secretion of
extracellular matrix proteins and growth factors. Astrocytes
were previously shown to produce laminin and ﬁbronectin
[104, 105]. Subsequent studies demonstrated T3-induced
expression of laminin and ﬁbronectin in cultured cerebellar
astrocytes and revealed that both laminin and ﬁbronectin
were organized in ﬁbrillar pattern on the cell surface,
while hypothyroid conditions changed this distribution for a
disorganized extracellular matrix of punctuate pattern [106].
As an underlying mechanism it was suggested that astrocytes
modulate extracellular matrix composition via T3-mediated
growth factor secretion [104, 107].
Basic ﬁbroblast growth factor (bFGF) and epidermal
growth factor (EGF) are secreted by cerebellar astrocytes in
response to T3 and seem to promote extracellular matrix
protein secretion and organization in an autocrine manner
[106]. EGF was suggested to exert its eﬀect on extracellular
matrix protein secretion through MAPK/phosphatidylino-
sitol 3-kinase pathway [108]. Astrocytes also secrete nerve
growth factor (NGF) in a T3-dependent manner, which
allows potent control of neurite growth and survival
[109–111].
Beyond T3, the eﬀect of T4 on astrocytes was also
demonstrated suggesting that thyroid hormone could also4 Journal of Thyroid Research
impact astrocytes via a nongenomic pathway. T4 exerts
its eﬀect on the microﬁlament network of astrocytes by
dynamically organizing F-actin ﬁlaments, facilitating inte-
grin clustering, and focal contact formation [112, 113].
Polymerizedactinﬁlamentnetworkwasobservedincultured
astrocytes after treatment with T4 and reverse T3 while T3
did not aﬀect the polimerization rate [114, 115].
Adhesive interactions among the extracellular matrix
protein laminin, integrins, and the microﬁlament network
play a fundamental role in the regulation of neural cell
migration during brain development. In vitro studies on
neurite development demonstrated that neurons, cocultured
with astrocytes under thyroid hormone-depleted conditions,
showed reduced total neurite length and decreased neurite
numbers [108]. As a consequence, these data suggest that
thyroid hormone-mediated actions on astrocytes are impor-
tant events in neuron migration and axon formation.
3. Thyroid Hormone Activation in Neuroglia
3.1. Regulation of Type 2 Deiodinase in Glial Cells. While
thyroid hormone impacts glial function in various manner
(see above), neuroglia is not only target but also the
predominant source of T3 in the brain. As mentioned
above, astrocytes and tanycytes express type 2 deiodinase
(D2), the enzyme catalyzing thyroid hormone activation.
Below, we will discuss factors and conditions aﬀecting D2
regulationinglialcells,sincetheycancontributetothebetter
understanding of thyroid hormone signaling in the brain.
3.1.1. Thyroid Hormone. D2 is negatively regulated by thy-
roid hormone, through a mechanism that involves product
(T3-) mediated transcriptional downregulation of the Dio2
gene and substrate (T4-) induced posttranslational decrease
of D2 protein levels (reviewed in [66], see Section 3.2). The
negative regulation of D2 activity suggests a homeostatic
regulation of T3 generation [116–118]. However, region-
speciﬁc diﬀerences within the brain regarding the response
to hyper- or hypothyroidism are reﬂected by changes in D2
regulation. D2 is reciprocally regulated by thyroid hormone
in various brain regions but shows only modest response in
the hypothalamus [19, 119–121]. The fact that D2 activity
in the hypothalamus is concentrated in tanycytes [19]
suggestsmarkeddiﬀerencesbetweenastrocytesandtanycytes
regarding thyroid hormone response and balance. While
in astrocytes T3 production seems to serve homeostatic
purposes, the relative insensitivity of D2 to T3 in tanycytes
would indicate that other signals act more importantly on
D2 expression, thus controlling local T3 production [25].
The mechanisms responsible for this diﬀerence between
astrocytes and tanycytes remain to be determined. However,
a link has been suggested between the developmental state
of astrocytes and their responsiveness to thyroid hormone
[38]. Although tanycytes are still considered as terminally
diﬀerentiated cells, data have been accumulating that at least
a subpopulation of this inhomogeneous cell layer might
behave as progenitor cells. This is supported by observations
that the tanycyte layer in the wall of the third ventricle regen-
erates in two weeks following alloxan-induced destruction
[122], and tanycytes could be considered a neurogenic niche
in response to IGF-I [123]. This is presently unclear whether
diﬀerences in diﬀerentiation stages or a more speciﬁc factor
is responsible for the diﬀerent responsiveness to thyroid
hormone of the two cell types.
3.1.2. Infection, Nonthyroidal Illness. It has been suggested
that D2-generated T3 in tanycytes of the mediobasal
hypothalamus could play a role in the pathogenesis of non-
thyroidal illness during infection [63, 66, 67, 124]. Nonthy-
roidal illness syndrome (euthyroid sick syndrome or low T3
syndrome) is accompanied by low T3 and sometimes low T4
serum levels and associated with nonelevated or inappropri-
ately elevated TSH levels during infection, sepsis, starvation,
malignancy,life-threateningtrauma,andothercriticalillness
[125–128]. Although the syndrome has been known for
decades, it is still a matter of debate whether the changes of
thyroid hormone proﬁle provide physiologic compensation
for illness or it represents pathological conditions [129–
131].Systemicadministrationofbacteriallipopolysaccharide
(LPS) increased D2 mRNA expression in tanycytes and
D2 activity in the rat mediobasal hypothalamus (Figure 1)
accompanied by falling serum thyroid hormone and TSH
levels [132]. This phenomenon was also observed in mice,
immediately followed by decreased expression of thyroid
receptor β2, TSHβ in the pituitary and decreased type 1
deiodinase mRNA in the pituitary and liver [133].
LPS induced suppression of TRH expression in the
hypothalamic paraventricular nucleus of wild type but the
eﬀect was abolished in the D2 knock-out mice (Figure 2)
(see Section 3.3)[ 23]. Although this model is not suitable to
dissect the role of speciﬁc glial subtypes in this mechanism,
it clearly demonstrated the fundamental role of D2 activity
in TRH suppression during infection and supported the
hypothesis of a close interaction between neurons and glial
cells and their role in regulating brain functions via T3
availability.Importantly,whilethecontinuousincreaseinD2
activity of cortical astrocytes seemed to be the consequence
of falling T4 levels, D2 activation in tanycytes followed
kinetics that was independent of thyroid hormone levels
[132, 134]. It was also demonstrated that LPS-induced
D2 expression on the mediobasal hypothalamus was not
dependent on circulating corticosterone, either [135]. Unex-
pectedly, cultured astrocytes of the rat cerebral hemispheres
increased their D2 activity in response to LPS, and glucocor-
ticoids enhanced this eﬀect [136]. It is presently not clear
why this eﬀect is not reﬂected in vivo by the kinetics of
cortical D2 induction. Importantly NF-κB ,ap o t e n te ﬀector
of LPS-induced signaling, transcriptionally activated the D2
encodingDio2gene,andafunctionalNF-κBbindingsitewas
identiﬁed and characterized in the human Dio25  ﬂanking
region [132, 137]. NF-κB was also involved in the LPS-
induced increase in D2 activity in cultured astrocytes [136].
Further studies on the kinetics of LPS-induced activation
of the NF-κB pathway in the rat mediobasal hypothalamus
indicated that NF-κB activation contributes to sustaining
the LPS-induced D2 response in a subset of α tanycytes
[138]. However, this is not the initiating mechanism of LPS-
induced D2 response in tanycytes. The same study suggestedJournal of Thyroid Research 5
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Figure 1: Infection upregulates D2 expression in tanycytes of the rat mediobasal hypothalamus. Dark-ﬁeld micrographs from three diﬀerent
rostrocaudal levels of the median eminence (ME) showing the eﬀect of i.p. LPS treatment on D2 mRNA expression. (a)–(c), Controls; (d)-
(f), LPS-treatment. Note: D2 in situ hybridization signal is increased in the tanycytes lining the wall of the third ventricle (III), and in the
tanycyteprocessesinthetuberoinfundibularsulci(arrows),intheexternalzoneoftheME.ARC,arcuatenucleus.Reprintedwithpermission
from Fekete et al. [132], The Endocrine Society.
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Figure 2: LPS-induced infection downregulates TRH mRNA expression in the hypothalamic paraventricular nucleus of wildtype but in D2
knock-out mice. (a,b), wild-type; (c,d), D2 KO mice; (a,c), control; (b,d), i.p. LPS-treated animals; (e), quantiﬁcation of the TRH mRNA
signal by densitometry. Printed from Freitas et al. American Society for Clinical Investigation [23].6 Journal of Thyroid Research
that TSH of the part tuberalis could also play a role in
this process [138]. The factor(s) that initiate tanycytal D2
induction in the starting phase of LPS-evoked infection
are presently not known. However, taking into account the
highly active nature of D2-catalyzed T3 generation even
a subpopulation of tanycytes could provide a signiﬁcant
amount of T3 for the modulation of TRH expression. To
asses this appropriately, it would be important to understand
in details the pathways that allow tanycyte-generated T3 to
reach hypophysiotropic TRH neurons in the paraventricular
nucleus.
3.1.3. Iodine. Iodine availability is critically important to
maintain proper thyroid hormone levels. During moderate
iodine deﬁciency most thyroid hormone target tissues are
only mildly aﬀected, due to rapid physiological adaptations
of the hypothalamo-hypophyseal-thyroid axis, which main-
tains plasma T3 at the normal range [139, 140]. Via glial D2
and neuronal D3, the brain is capable of adapting to iodine
deﬁciency in a complex manner. A moderately severe iodine
deﬁciencyresultedinincreasedD2mRNAandactivityindif-
ferent brain regions [140]. D2 sensitivity to iodine deﬁciency
was region speciﬁc, the hippocampus and cerebral cortex
representedthemostresponsiveregions.D2inductioninthis
regionsindicatedthatastrocytesincreasetheirT3-generating
activity under iodine deﬁciency. Tanycytes of the mediobasal
hypothalamusalsoincreasedtheirD2expressionandactivity
although their response was lower compared to astrocytes in
the cortex and hippocampus. Since increase of D2 activity
was higher than that of mRNA expression, it could be
speculated that not only pretranslational events are involved
here in D2 regulation but also prolonged D2 half-life
due to decreased D2 ubiquitination (see Section 3.2)c o u l d
contribute to this eﬀect. Increased glial D2 in iodine deﬁ-
ciency was paralleled with reduced neuronal D3 [140]. Thus
mitigating the eﬀects of iodine deﬁciency by both increased
T3 generation and reduced T3 degradation reﬂected the
particular importance of adaptation of the brain to iodine
deﬁciency. Various aspects of iodine deﬁciency modulated
alterationsofthyroidhormonedeiodinationwereextensively
reviewed elsewhere [141].
3.1.4. Fasting. D2 expression in tanycytes is modulated by
food restriction. Fasting resulted in twofold increase in D2
mRNA expression and activity in rat mediobasal hypotha-
lamus, and it was straightforward to suggest that this could
suppress TRH expression in the hypothalamic paraventric-
ular nucleus and downregulate this way the hypothalamo-
hypophyseal-thyroid axis. [121]. However, fasting-mediated
decrease of TRH expression in the paraventricular nucleus
of the TRβ2-null transgenic mice remained unaﬀected
although TRβ2 represents the key TR isoform involved in
T3-mediatednegativeregulationofTRHexpressionintrans-
genic mice [142]. This ﬁnding demonstrated that tanycyte-
generated T3 during fasting should not have major direct
eﬀects on TRH expression in the paraventricular nucleus.
As an alternative pathway, the hypothalamic ventromedial
nucleus was also suggested as a target translating changing
hypothalamic T3 levels into the modulation of food intake
[143]. The role of glial D2-mediated hypothalamic T3 in
fasting is not yet resolved, and related data are reviewed
elsewhere [25, 61, 63, 66].
3.1.5. Light. D2 expression in the mediobasal hypothalamus
is controlled by light, and this has consequences on repro-
ductive function. Light exposure-induced D2 expression
in the mediobasal hypothalamus of the Japanese quail
(Coturnix japonica) represents a crucial event in the signal
transduction pathway ensuring photoperiodic response of
gonads. Intracerebroventricular administration of T3 mim-
icked the photoperiodic response, whereas the D2 inhibitor
iopanoic acid prevented gonadal growth [144]. Interestingly,
beyond median eminence and infundibular nucleus D2
induction was also observed in the dorsal and lateral
hypothalamus. Based on this ﬁnding it cannot be excluded
that not only tanycytes but other cell types, for example,
hypothalamic astrocytes could be also involved in this mech-
anism, but this aspect was not studied in details. A mech-
anism for light-induced D2 expression in the mediobasal
hypothalamuswasalsorevealedinquailshowingapreceding
peak of TSHβ-subunit expression in the pars tuberalis via
a cAMP-dependent mechanism. It was demonstrated that
intracerebroventricular administration of TSH to short-day
quail stimulated gonadal growth and D2 expression and
proved that TSH in the pars tuberalis therefore seems to
trigger long-day photoinduced seasonal breeding [145].
A homology between avian and mammalian photope-
riodic regulation of reproduction has been observed since
D2 expression was also increased in Djungarian (Siberian)
hamsters (Phodopus sungorus) under long days; the signal
was weaker under short days while melatonin injection
decreasedD2expressionunderlongdays[146].Theseresults
indicate that D2 expression in tanycytes may be involved in
the regulation of seasonal reproduction both in mammals
andbirds.Regulationofseasonalreproductionbyphotoperi-
odic regulation of hypothalamic thyroid hormone levels also
involves reciprocal changes of D2 and D3 expression that
is reviewed elsewhere along with data on other models of
seasonal reproduction [66, 147, 148].
3.1.6. Trauma. After traumatic brain injury D2 mRNA was
upregulated in reactive astrocytes in rat. In the cerebral
cortex near the contusion D2 mRNA was upregulated on
the ﬁrst day after injury; in the following days the signal
was shown to have expanded to the hippocampus, where
the astrocytic localization of upregulated D2 mRNA was
obvious and bordered the neuronal granule cell layer [149].
Furthermore, diﬀerent stressors including relatively mild
ones (e.g., handling) increased D2 activity in a stressor- and
brain-region dependent manner [150]. The frontal cortex
showed the highest D2 response, and motor stress was
the most dominant stressor in this region while no eﬀect
was seen in the cerebellum. A stressor-dependent decrease
of T4 tissue concentration was also observed but stressor-
dependent deviations were also found since, for example,
gently handling resulted in elevated T4 in the frontal cortex.Journal of Thyroid Research 7
A strict correlation between D2 activity and tissue T4 levels
could not be found suggesting the role of speciﬁc factors and
not simply the falling T4 level in stress-related D2 increase
[150].
3.1.7. Development. Deiodinases are tightly regulated during
v a r i o u sd e v e l o p m e n t a lp r o c e s s e s( r e v i e w e di n[ 4, 151]). It
was shown that the human fetal brain is already sensitive to
thyroid hormones before the onset of the fetal thyroid [152,
153]. The presence of high-aﬃnity T3 binding sites with a
speciﬁcity that resembles that of the nuclear T3 receptors
was also demonstrated in the human fetal brain and its
concentration increased by tenfold from ten to sixteen weeks
[154]. D2 expression and activity was detected in the human
fetal cortex already from seven to eight weeks of gestation
[155]. It has been also demonstrated that during the second
trimester T3 increases in the cortex due to D2 activity, while
it remains very low in cerebellum because of D3-mediated
thyroid hormone inactivation [156]. Although deiodinase
activities were also studied in the developing rat brain, [157],
dataarelimitedonontogenicaspectsofD2expressionindif-
ferent glial subtypes. Increasing D2 expression was detected
in the developing chicken brain in perivascular localizations
probably localized to glial cells [158]. It was also demon-
strated that D2 was expressed in chicken tanycytes before
the onset of thyroid hormone-dependent negative feedback.
Furthermore, D2 and Nkx2.1 were coexpressed at E13 and
P2 in tanycytes but not in the perivascular glia indicating a
glial-subtype-speciﬁc regulation of D2 expression [159].
3.1.8. Other Factors. It has been demonstrated that D2
expression in glial cells is under the control of multiple
factors. These include the increase of D2 activity upon cAMP
induction [160, 161] that is in line with the ﬁnding of
an evolutionary conserved CRE site in the Dio2p r o m o t e r
[61, 162–164]. Selenium dependence [165], phorbol esters
and glucocorticoids [166], acidic ﬁbroblast growth factor
[167] also impact D2 activity.
3.2. Posttranslational Regulation of Glial D2 Activity. It has
been demonstrated that D2 activity in the brain undergoes
rapid and substrate-induce changes [116, 117]. The under-
lying mechanism was later identiﬁed demonstrating that
D2 undergoes substrate-induced ubiquitination followed by
its degradation in the proteasome [168–170]. This was a
unique example of substrate-induced selective proteolysis
that involves ubiquitination of an endoplasmic reticulum
resident enzyme and represented the ﬁrst demonstration
that such a regulatory pathway controls activation of a
hormone [170] .T h ep a t h w a yw o r k sa l s oi np r i m a r yc u l t u r e s
of astrocytes, since MG132 a proteasome uptake inhibitor
could block substrate-induced D2 inactivation [171]. Inter-
estingly, D2 inactivation via ubiquitination does not neces-
sarily involve proteasomal proteolysis. It has been revealed
that D2 forms homodimers that undergo ubiquitination-
mediated transient and reversible conformation changes.
Since dimerization of D2 monomers is crucial to maintain
the proper conformation of the active center of the enzyme,
ubiquitination-mediated changes result in the rapid loss of
D2 activity [172].
Since D2 ubiquitination represents a rapid way for the
regulation of T3 generation its mechanism was studied in
detail in the past several years. UBC6 and 7 were identiﬁed as
the ubiquitin conjugases (E2) involved in the ubiquitination
of D2 [173, 174], while USP-33 and USP-20 (VDU1 and 2)
deubiquitinate D2 and prolong its half-life [175]. A novel
type of ubiquitination motif containing a 18-aa-loop struc-
ture of the D2 protein was identiﬁed and characterized [176,
177]. WSB1 (Swip1) was recognized as a sonic hedgehog-
induced SOCS-box containing protein of unknown function
[178, 179]. Importantly, it could be shown that WSB1 serves
as the ubiquitin ligase (E3) that links D2 to the Elongin
BC-Cul5-Rbx1 ubiquitinating catalytic core complex [176].
Later, Teb4 has been also identiﬁed as a D2 E3 ligase [180].
Data are accumulating on how crucial elements of the
D2ubiquitination machinery are expressed inD2-expressing
glial subtypes. The available data revealed cell-type-speciﬁc
diﬀerences in the expression of crucial elements of the
D2 ubiquitinating/deubiquitinating machinery in the
rodent brain. WSB1, the D2 E3 ligase, is expressed both in
GFAP-expressing astrocytes in diﬀerent brain regions and
in tanycytes in the mediobasal hypothalamus (Figure 3)
[181]. This suggested that the WSB1-D2 interaction, a
process required for D2 ubiquitination, could be functional
in these cells. In contrast to WSB1, the TEB4 E3 ligase
could not be detected in GFAP-expressing astrocytes, only
in the cerebellum, but it was expressed in tanycytes [180].
Furthermore, the USP33 (VDUI) D2 deubiquitinase is
co-expressed with D2 only in tanycytes but not in astrocytes
(Figure 3)[ 181]. WSB1 and USP33 expression in the brain
was not aﬀected by thyroid hormone status indicating that
these genes are not involved in the homeostatic response to
hypo- or hyperthyroidism [181].
The available data suggested that kinetics of D2 ubiqui-
tination and consequent selective proteolysis in the protea-
some could be diﬀerent among diﬀerent subtypes of glial
cells. Among D2-expressing cell types of the brain, tanycytes
express the most comprehensive set of genes involved in
ubiquitination-mediated D2 regulation, that ensures both
WSB1- and TEB4-mediated ubiquitination ligation to D2-
and also USP33 deubiquitinase-mediated D2 reactivation. In
astrocytes D2 deubiquitinaton is either not possible, or it
works via USP20 or other unidentiﬁed D2 deubiquitinases.
3.3.NeuroglialThyroidHormoneMetabolismAﬀectsNeuronal
Gene Expression. Astrocytes and tanycytes of the neuroglial
compartment are the predominant source of T3 present in
the brain while TR in neurons represents a major target of
thyroidhormone.Asdiscussedabove,neuronscannotgener-
ate T3 but express type 3 deiodinase (D3), the T3 degrading
enzyme. While numerous observations suggested that glial
thyroid hormone metabolism could aﬀect neuronal function
(see Section 3.1), until recently no direct evidence could
be obtained to prove the existence of deiodinase-mediated
transcriptional T3 footprints in neurons. Recently a two-
dimensional coculture was used based on the D2-expressing8 Journal of Thyroid Research
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Figure 3: Expression of crucial elements of the D2 ubiquitination machinery in glial cells in the rat brain. (a,b) mRNA of WSB1, the D2
ubiquitin ligase is expressed in tanycytes lining the wall of the third ventricle (3V). WSB1 expression (arrows) extended from the anterior
lower part (not shown) to the lower two thirds of the wall of the third ventricle in more caudal regions. Neuronal cells also express WSB1.
(c,d) Hybridization signal of the USP33 D2 deubiquitinase was also detected over tanycytes and ependymal cells lining all regions of the
wall of the third ventricle (arrows). Neuronal cells also express USP33. (e) WSB1 in situ hybridization signal (arrows) is observed over the
majority of GFAP-expressing astrocytes (brown immunoreactivity) demonstrated here in the hippocampal dentate gyrus. (f) The mRNA
of USP33 was absent from GFAP-expressing astrocytes (brown) in the hippocampus, but it was expressed in granular neurons. The sense
probes for WSB1 or USP33 did not produce any signal (not shown). Mol, molecular layers of the dentate gyrus; GrDG, granular layer of the
dentate gyrus; PoDG, polymorph layer of the dentate gyrus. Reprinted with permission from Fekete et al. [181] The Endocrine Society.
H4 glioma cells and the D3-expressing SK-N-AS neuronal
cellline.IthasbeenshownthatT4couldactivatetheendoge-
nously expressed T3-sensitive ENPP2 gene of the neuronal
compartment only if the glial compartment was present.
This model led to the demonstration that D2-mediated
glial T3 generation from physiological amount of T4 can
directly aﬀect thyroid hormone-dependent gene expression
in a paracrine fashion [23]. A diﬀerent approach using
expression proﬁling-based assessment of thyroid-hormone-
regulatedgeneexpressioninthecerebralcortexoftheMCT8,
D2, and MCT8/D2 knock-out mice suggested that negative
regulation required D2-generated T3, while peripheral T3
entering the brain should be suﬃcient to maintain normal
expression of positively regulated genes [59].
Speciﬁcsignalsashedgehog proteins [176,182],bacterial
lipopolysaccharide (LPS) [132, 133, 137, 183], and hypoxia
[184]havebeenestablishedasregulatorsofdeiodinaseactivi-
ties.Itwasalsostudiedhowthesespeciﬁcsignalsimpactneu-
roglial thyroid hormone metabolism in the coculturesystem.
The sonic hedgehog morphogene decreases glial thyroidJournal of Thyroid Research 9
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Figure 4: Proposed model of neuroglia-neuron interaction of thyroid hormone signaling in the brain. D2 activates the prohormone T4
in glial cells (astrocytes and tanycytes); the generated T3 exits the glial compartment and enters adjacent neurons, where it establishes
a transcriptional footprint via liganding TR. Only the two best-characterized thyroid hormone transporters, OATP1C1 and MCT8, are
indicated, but data are also accumulating on the role of LAT1 and LAT2 in the thyroid hormone transport both in neurons and astrocytes
(discussed in Section 1). In the glial compartment LPS activates D2 transcription while sonic hedgehog (Shh) promotes D2 inactivation
via WSB1—mediated ubiquitination; both hypoxia and Shh activate D3 gene transcription in neurons. Figure modiﬁed from Freitas et al.
American Society for Clinical Investigation [23].
hormone activation via WSB1-mediated posttranslational
downregulation of D2 (see Section 3.2) and increases
neuronal D3 expression [23]. This demonstrates the
existence of a mechanism ensuring a ﬁne-tuned balance
between sonic hedgehog-mediated proliferation and T3-
evoked diﬀerentiation. This is interesting since astrocytes
are targets of sonic hedgehog signaling [185]. It has been
also demonstrated that in the brain T3 upregulates crucial
elements of the sonic hedgehog signaling pathway that
could represent a compensatory feedback loop for sonic
hedgehog-mediated T3 regulation [186].
The eﬀect of LPS on D2 expression and its relation to
nonthyroidal illness were discussed in Section 3.1.I n
contrast to sonic hedgehog, LPS-induced glial D2 activity
and decreased neuronal D3 in the H4-SK-N-AS system and
as a consequence resulted in a decreased T3-mediated gene
expression in the neuronal compartment [23]. These data
were complemented with in vivo observation on the LPS
evoked model of nonthyroidal illness. LPS could not induce
TRH suppression on the paraventricular nucleus of the
D2 knock-out mice only in wild types (Figure 2) (see also
Section 3.1). This indicated that glial (highly probably tany-
cytal) D2-generated T3 in the hypothalamus could play an
important role in T3-mediated suppression of the hypophys-
iotropic TRH neurons and consequently in the decreased
activity of the hypothalamo-hypophyseal-thyroid axis
during the infection-evoked subtype of nonthyroidal illness
[23].
In contrast, hypoxia aﬀected predominantly neuronal
D3 activity in the H4- SK-N-AS system. This eﬀect could
be also demonstrated in a rat in vivo hypoxia/ischemia
model showing D3 induction in cortical neurons and in
the hippocampal pyramidal and granular cell layers [23].
This suggested that lowered local T3 levels improve neu-
ronal survival under hypoxic challenge. The glial aspect of
this phenomenon requires further studies since an inde-
pendent study on primary cultures of astrocytes demon-
strated hypoxia-induced increase of D2 activity [171]. These
data established deiodinase enzymes as glial and neuronal
control points for the regulation of thyroid hormone
action in the brain during health and disease (Figure 4)
[23].10 Journal of Thyroid Research
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